Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man. 1981

I Magnussen, and T S Jensen, and J H Rand, and M H Van Woert

Single oral doses of L-5-hydroxytryptophan (5-HTP) were administered in combination with L-aromatic amino acid decarboxylase inhibitors. The time courses of plasma concentrations of 5-HTP, 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) and the concentrations of 5-HT in blood platelets were measured. Carbidopa enhanced the rise in plasma concentrations of 5-HTP 5-15 fold and counteracted the increase in plasma 5-HIAA levels induced by 5-HTP alone. A single dose of the decarboxylase inhibitor was equipotent to 14 days' pretreatment. Plasma or platelet concentrations of 5-HT failed to reflect the metabolism of 5-HTP. The ratio of 5-HTP to carbidopa influenced the systemic bioavailability of single dose administered 5-HTP indicating dose dependent absorption kinetics. Co-administration of L-dopa with 5-HTP and decarboxylase inhibitors had no effect on gastrointestinal absorption of 5-HTP in six parkinsonian patients.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D002230 Carbidopa An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself. Methyldopahydrazine,Carbidopa, (R)-Isomer,Carbidopa, (S)-Isomer,Lodosin,Lodosyn,MK-485,MK-486,MK 485,MK 486,MK485,MK486
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006897 Hydroxyindoleacetic Acid 5-HIAA,5-Hydroxy-3-Indoleacetic Acid,5-Hydroxyindolamine Acetic Acid,5 Hydroxy 3 Indoleacetic Acid,5 Hydroxyindolamine Acetic Acid,Acetic Acid, 5-Hydroxyindolamine,Acid, 5-Hydroxy-3-Indoleacetic,Acid, 5-Hydroxyindolamine Acetic,Acid, Hydroxyindoleacetic
D006916 5-Hydroxytryptophan The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant. 5-HTP,Hydroxytryptophan,Oxitriptan,Oxytryptophan,Tryptophan, 5-Hydroxy-,5 Hydroxytryptophan,5-Hydroxy- Tryptophan,Tryptophan, 5 Hydroxy
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012701 Serotonin A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator. 5-HT,5-Hydroxytryptamine,3-(2-Aminoethyl)-1H-indol-5-ol,Enteramine,Hippophaine,Hydroxytryptamine,5 Hydroxytryptamine
D065105 Aromatic Amino Acid Decarboxylase Inhibitors Compounds and drugs that block or inhibit the enzymatic action of AROMATIC AMINO ACID DECARBOXYLASES. Pharmaceutical agents in this category are used in conjunction with LEVODOPA in order to slow its metabolism. Aromatic-L-Amino-Acid Decarboxylase Inhibitors,DOPA Decarboxylase Inhibitors,Dihydroxyphenylalanine Decarboxylase Inhibitors,Aromatic L Amino Acid Decarboxylase Inhibitors,Decarboxylase Inhibitors, Aromatic-L-Amino-Acid,Decarboxylase Inhibitors, DOPA,Decarboxylase Inhibitors, Dihydroxyphenylalanine,Inhibitors, Aromatic-L-Amino-Acid Decarboxylase,Inhibitors, DOPA Decarboxylase,Inhibitors, Dihydroxyphenylalanine Decarboxylase

Related Publications

I Magnussen, and T S Jensen, and J H Rand, and M H Van Woert
April 1980, Acta pharmacologica et toxicologica,
I Magnussen, and T S Jensen, and J H Rand, and M H Van Woert
April 1979, Acta pharmacologica et toxicologica,
I Magnussen, and T S Jensen, and J H Rand, and M H Van Woert
January 1999, Advances in experimental medicine and biology,
I Magnussen, and T S Jensen, and J H Rand, and M H Van Woert
September 1969, British journal of pharmacology,
I Magnussen, and T S Jensen, and J H Rand, and M H Van Woert
May 2022, Journal of veterinary pharmacology and therapeutics,
I Magnussen, and T S Jensen, and J H Rand, and M H Van Woert
April 1974, The Journal of clinical endocrinology and metabolism,
I Magnussen, and T S Jensen, and J H Rand, and M H Van Woert
August 1996, Clinical science (London, England : 1979),
I Magnussen, and T S Jensen, and J H Rand, and M H Van Woert
December 1974, Endocrinologia japonica,
I Magnussen, and T S Jensen, and J H Rand, and M H Van Woert
March 1959, Postgraduate medicine,
Copied contents to your clipboard!